Cost-effectiveness of Single-dose Zoledronic Acid for Nursing Home Residents with Osteoporosis in the USA

Overview

Journal BMJ Open

Specialty General Medicine

Date 2018 Sep 6

PMID 30181186

Citations 5

Authors

Kouta Ito

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the cost-effectiveness of routine administration of single-dose zoledronic acid for nursing home residents with osteoporosis in the USA.

Design: Markov cohort simulation model based on published literature from a healthcare sector perspective over a lifetime horizon.

Setting: Nursing homes.

Participants: A hypothetical cohort of nursing home residents aged 85 years with osteoporosis.

Interventions: Two strategies were compared: (1) a single intravenous dose of zoledronic acid 5 mg and (2) usual care (supplementation of calcium and vitamin D only).

Primary And Secondary Outcome Measures: Incremental cost-effectiveness ratio (ICER), as measured by cost per quality-adjusted life year (QALY) gained.

Results: Compared with usual care, zoledronic acid had an ICER of $207 400 per QALY gained and was not cost-effective at a conventional willingness-to-pay threshold of $100 000 per QALY gained. The results were robust to a reasonable range of assumptions about incidence, mortality, quality-of-life effects and the cost of hip fracture and the cost of zoledronic acid. Zoledronic acid had a potential to become cost-effective if a fracture risk reduction with zoledronic acid was higher than 23% or if 6-month mortality in nursing home residents was lower than 16%. Probabilistic sensitivity analysis showed that the zoledronic acid would be cost-effective in 14%, 27% and 44% of simulations at willingness-to-pay thresholds of $50 000, $100 000 or $200 000 per QALY gained, respectively.

Conclusions: Routine administration of single-dose zoledronic acid in nursing home residents with osteoporosis is not a cost-effective use of resources in the USA but could be justifiable in those with a favourable life expectancy.

Citing Articles

Economic evaluation of a national vitamin D supplementation program among Iranian adolescents for the prevention of adulthood type 2 diabetes mellitus.

Zandieh N, Hemami M, Darvishi A, Hasheminejad S, Abdollahi Z, Zarei M BMC Complement Med Ther. 2022; 22(1):1.

PMID: 34980092 PMC: 8722369. DOI: 10.1186/s12906-021-03474-0.

Intravenous bisphosphonate therapy does not delay fracture healing in inter-trochanteric femur fractures - A randomised controlled study.

Jalan H, Perumal R, Prabhu S, Palanivelayutham S, Viswanathan V, Rajasekaran S J Clin Orthop Trauma. 2021; 20:101472.

PMID: 34178598 PMC: 8213889. DOI: 10.1016/j.jcot.2021.06.002.

An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis.

Li N, Cornelissen D, Silverman S, Pinto D, Si L, Kremer I Pharmacoeconomics. 2020; 39(2):181-209.

PMID: 33026634 PMC: 7867562. DOI: 10.1007/s40273-020-00965-9.

Systematic evidence of health economic evaluation of drugs for postmenopausal osteoporosis: A quality appraisal.

Azharuddin M, Adil M, Khan R, Ghosh P, Kapur P, Sharma M Osteoporos Sarcopenia. 2020; 6(2):39-52.

PMID: 32715093 PMC: 7374246. DOI: 10.1016/j.afos.2020.05.006.

Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China.

You R, Zhang Y, Wu D, Liu J, Qian X, Luo N Front Pharmacol. 2020; 11:456.

PMID: 32425768 PMC: 7203488. DOI: 10.3389/fphar.2020.00456.

References

Ohsfeldt R, Borisov N, Sheer R . Fragility fracture-related direct medical costs in the first year following a nonvertebral fracture in a managed care setting. Osteoporos Int. 2005; 17(2):252-8. DOI: 10.1007/s00198-005-1993-2. View

Greenspan S, Schneider D, McClung M, Miller P, Schnitzer T, Bonin R . Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002; 136(10):742-6. DOI: 10.7326/0003-4819-136-10-200205210-00009. View

Greenspan S, Perera S, Ferchak M, Nace D, Resnick N . Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med. 2015; 175(6):913-21. PMC: 4843134. DOI: 10.1001/jamainternmed.2015.0747. View

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

Beaupre L, Jones C, Johnston D, Wilson D, Majumdar S . Recovery of function following a hip fracture in geriatric ambulatory persons living in nursing homes: prospective cohort study. J Am Geriatr Soc. 2012; 60(7):1268-73. DOI: 10.1111/j.1532-5415.2012.04033.x. View

Colon-Emeric C, Datta S, Matchar D . An economic analysis of external hip protector use in ambulatory nursing facility residents. Age Ageing. 2003; 32(1):47-52. DOI: 10.1093/ageing/32.1.47. View

Zimmerman S, Magaziner J, Birge S, Barton B, Kronsberg S, Kiel D . Adherence to hip protectors and implications for U.S. long-term care settings. J Am Med Dir Assoc. 2010; 11(2):106-15. PMC: 2846526. DOI: 10.1016/j.jamda.2009.09.013. View

Ito K, Elkin E, Girotra M, Morris M . Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med. 2010; 152(10):621-9. PMC: 5468170. DOI: 10.7326/0003-4819-152-10-201005180-00002. View

Parikh S, Brookhart M, Stedman M, Avorn J, Mogun H, Solomon D . Correlations of nursing home characteristics with prescription of osteoporosis medications. Bone. 2011; 48(5):1164-8. PMC: 3096758. DOI: 10.1016/j.bone.2011.02.006. View

10.

Honkanen L, Schackman B, Mushlin A, Lachs M . A cost-benefit analysis of external hip protectors in the nursing home setting. J Am Geriatr Soc. 2005; 53(2):190-7. DOI: 10.1111/j.1532-5415.2005.53102.x. View

11.

DesHarnais Castel L, Bajwa K, Markle J, Timbie J, Zacker C, Schulman K . A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer. 2001; 9(7):545-51. DOI: 10.1007/s005200100249. View

12.

Ito K, Blinder V, Elkin E . Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. J Clin Oncol. 2012; 30(13):1468-75. DOI: 10.1200/JCO.2011.38.7001. View

13.

Boonen S, Eastell R, Su G, Mesenbrink P, Cosman F, Cauley J . Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis. J Bone Miner Res. 2012; 27(7):1487-93. PMC: 3636532. DOI: 10.1002/jbmr.1605. View

14.

Ito K, Hollenberg J, Charlson M . Using the osteoporosis self-assessment tool for referring older men for bone densitometry: a decision analysis. J Am Geriatr Soc. 2009; 57(2):218-24. DOI: 10.1111/j.1532-5415.2008.02110.x. View

15.

Parikh S, Avorn J, Solomon D . Pharmacological management of osteoporosis in nursing home populations: a systematic review. J Am Geriatr Soc. 2009; 57(2):327-34. DOI: 10.1111/j.1532-5415.2008.02119.x. View

16.

Reid I, Black D, Eastell R, Bucci-Rechtweg C, Su G, Hue T . Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams. J Clin Endocrinol Metab. 2013; 98(2):557-63. DOI: 10.1210/jc.2012-2868. View

17.

Chandler J, Zimmerman S, Girman C, Martin A, Hawkes W, Hebel J . Low bone mineral density and risk of fracture in white female nursing home residents. JAMA. 2000; 284(8):972-7. DOI: 10.1001/jama.284.8.972. View

18.

Boonen S, Black D, Colon-Emeric C, Eastell R, Magaziner J, Eriksen E . Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc. 2010; 58(2):292-9. PMC: 3660706. DOI: 10.1111/j.1532-5415.2009.02673.x. View

19.

Zimmerman S, Girman C, Buie V, Chandler J, Hawkes W, Martin A . The prevalence of osteoporosis in nursing home residents. Osteoporos Int. 1999; 9(2):151-7. DOI: 10.1007/s001980050129. View

20.

Ito K, Leslie W . Cost-effectiveness of fracture prevention in rural women with limited access to dual-energy X-ray absorptiometry. Osteoporos Int. 2015; 26(8):2111-9. DOI: 10.1007/s00198-015-3107-0. View